Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States
B/F/TAF was associated with higher persistence than other ART regimens among older PWH. Findings underscore the importance of tailored ART selection to address the unique challenges faced by older PWH.
Authors
- Peter McMahon (ORCID: https://orcid.org/0000-0002-4947-2952)
- Amanda M. Kong (ORCID: https://orcid.org/0000-0002-6210-4185)
- Daisha Joseph
- Jacqueline Lucia
- Daniela Yucuma
- Uche Mordi
- Neia Prata Menezes
- Travis Lim
- Mary J. Christoph
- Gulce Askin
Institutions
- Aetion (United States) (US)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- Drugs & Aging
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1007/s40266-026-01279-9
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences